XML 68 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revisions of Previously-Issued Financial Statements - Summary of Effect of Corrections on Previously Reported Consolidated Balance Sheets (Detail) - USD ($)
$ in Millions
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Current assets:        
Cash and cash equivalents $ 110.9 $ 102.4 $ 68.5 $ 64.1
Marketable investment securities 69.7 48.3    
Prepaid expenses 9.4 12.7    
Inventory 34.3 42.2    
Trade accounts receivable, less allowance for doubtful accounts of $7.6 in 2017 98.3 90.2    
Prepaid taxes   0.2    
Other receivables 3.8 5.7    
Total current assets 326.4 301.7    
Property, plant and equipment, net 43.2 51.1    
Long-term marketable investment securities 30.7 48.5    
Intangibles, net 455.2 491.5    
Goodwill 318.6 316.1 195.3  
Total assets 1,174.1 1,208.9    
Current liabilities:        
Accounts payable 26.0 22.0    
Accrued liabilities 68.3 65.6    
Short-term contingent consideration 5.3 127.3    
Deferred revenue 2.6 2.6    
Total current liabilities 102.2 217.5    
Unrecognized tax benefits 24.9 25.2    
Other long-term liabilities 6.3 7.2    
Contingent consideration 9.2 13.2    
Long-term debt 9.3 99.1    
Long-term deferred taxes 57.3 78.7    
Total liabilities 209.2 440.9    
Commitments and contingencies    
Stockholders’ equity:        
Common stock, 68.4 shares outstanding at June 30, 2017 0.7 0.7    
Additional paid-in capital 915.4 851.4    
Accumulated other comprehensive loss (4.1) (5.5)    
Retained earnings (deficit) 52.9 (78.2)    
Total Myriad Genetics, Inc. stockholders' equity 964.9 768.4 $ 739.6 $ 661.7
Non-controlling interest   (0.4)    
Total stockholders' equity 964.9 768.0    
Total liabilities and stockholders’ equity $ 1,174.1 1,208.9    
As Reported [Member]        
Current assets:        
Cash and cash equivalents   102.4    
Marketable investment securities   48.3    
Prepaid expenses   12.7    
Inventory   42.2    
Trade accounts receivable, less allowance for doubtful accounts of $7.6 in 2017   105.6    
Prepaid taxes   0.2    
Other receivables   5.7    
Total current assets   317.1    
Property, plant and equipment, net   51.1    
Long-term marketable investment securities   48.5    
Intangibles, net   491.6    
Goodwill   316.1    
Total assets   1,224.4    
Current liabilities:        
Accounts payable   22.0    
Accrued liabilities   65.6    
Short-term contingent consideration   127.3    
Deferred revenue   2.6    
Total current liabilities   217.5    
Unrecognized tax benefits   25.2    
Other long-term liabilities   7.2    
Contingent consideration   13.2    
Long-term debt   99.1    
Long-term deferred taxes   84.4    
Total liabilities   446.6    
Commitments and contingencies      
Stockholders’ equity:        
Common stock, 68.4 shares outstanding at June 30, 2017   0.7    
Additional paid-in capital   851.4    
Accumulated other comprehensive loss   (5.5)    
Retained earnings (deficit)   (68.4)    
Total Myriad Genetics, Inc. stockholders' equity   778.2    
Non-controlling interest   (0.4)    
Total stockholders' equity   777.8    
Total liabilities and stockholders’ equity   1,224.4    
Adjustment [Member]        
Current assets:        
Trade accounts receivable, less allowance for doubtful accounts of $7.6 in 2017   (15.4)    
Total current assets   (15.4)    
Intangibles, net   (0.1)    
Total assets   (15.5)    
Current liabilities:        
Long-term deferred taxes   (5.7)    
Total liabilities   (5.7)    
Commitments and contingencies      
Stockholders’ equity:        
Retained earnings (deficit)   (9.8)    
Total Myriad Genetics, Inc. stockholders' equity   (9.8)    
Total stockholders' equity   (9.8)    
Total liabilities and stockholders’ equity   $ (15.5)